Therapy Detail

Therapy Name MVA-MUC1-IL2 vaccine + Nivolumab
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
MVA-MUC1-IL2 vaccine TG4010 MVA-MUC1-IL2 is a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2), for immunotherapy in cancer patients whose tumors express the MUC1 antigen (NCI Drug Dictionary).
Nivolumab Opdivo MDX-1106|BMS-936558 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (NCI Drug Dictionary). Opdivo (nivolumab) is FDA approved for the treatment of metastatic melanoma, squamous NSCLC, metastatic small cell lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, urothelial carcinoma, Hodgkin's lymphoma, hepatocellular carcinoma, and for dMMR or MSI-H colorectal cancer as a single agent or in combination with Yervoy (ipilimumab) (
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT03353675 Phase II MVA-MUC1-IL2 vaccine + Nivolumab A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT02823990 Phase II MVA-MUC1-IL2 vaccine + Nivolumab TG4010 and Nivolumab in Patients With Lung Cancer Active, not recruiting